Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma

Health-related quality of life (HRQOL) is increasingly recognised as an important end-point in cancer clinical trials. The concept of minimally important difference (MID) enables interpreting differences and changes in HRQOL scores in terms of clinical meaningfulness. We aimed to estimate MIDs for interpreting group-level change of European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 (EORTC QLQ-C30) scores in patients with malignant melanoma.

Source: European Journal of Cancer - October 22, 2018 Category: Cancer & Oncology Authors: Jammbe Z. Musoro, Andrew Bottomley, Corneel Coens, Alexander MM. Eggermont, Madeleine T. King, Kim Cocks, Mirjam AG. Sprangers, Mogens Groenvold, Galina Velikova, Hans-Henning Flechtner, Yvonne Brandberg, the EORTC Melanoma Group and EORTC Quality of Life Tags: Original Research Source Type: research